NO20004170L - FremgangsmÕte ved fremstilling av muse og humant endostatin - Google Patents

FremgangsmÕte ved fremstilling av muse og humant endostatin

Info

Publication number
NO20004170L
NO20004170L NO20004170A NO20004170A NO20004170L NO 20004170 L NO20004170 L NO 20004170L NO 20004170 A NO20004170 A NO 20004170A NO 20004170 A NO20004170 A NO 20004170A NO 20004170 L NO20004170 L NO 20004170L
Authority
NO
Norway
Prior art keywords
mouse
preparation
human endostatin
endostatin
human
Prior art date
Application number
NO20004170A
Other languages
English (en)
Other versions
NO20004170D0 (no
Inventor
Elisabeth I Harding
Bernard N Violand
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of NO20004170D0 publication Critical patent/NO20004170D0/no
Publication of NO20004170L publication Critical patent/NO20004170L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20004170A 1998-02-23 2000-08-21 FremgangsmÕte ved fremstilling av muse og humant endostatin NO20004170L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7558798P 1998-02-23 1998-02-23
PCT/US1999/003271 WO1999042486A1 (en) 1998-02-23 1999-02-19 Method of producing mouse and human endostatin

Publications (2)

Publication Number Publication Date
NO20004170D0 NO20004170D0 (no) 2000-08-21
NO20004170L true NO20004170L (no) 2000-10-23

Family

ID=22126741

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004170A NO20004170L (no) 1998-02-23 2000-08-21 FremgangsmÕte ved fremstilling av muse og humant endostatin

Country Status (15)

Country Link
US (1) US6653098B1 (no)
EP (1) EP1056780A1 (no)
JP (1) JP2002504494A (no)
KR (1) KR20010034529A (no)
CN (1) CN1295580A (no)
AU (1) AU766154C (no)
BR (1) BR9908186A (no)
CA (1) CA2321958A1 (no)
CZ (1) CZ20003058A3 (no)
IL (1) IL137995A0 (no)
NO (1) NO20004170L (no)
NZ (1) NZ506466A (no)
PL (1) PL342495A1 (no)
RU (1) RU2225728C2 (no)
WO (1) WO1999042486A1 (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US7153943B2 (en) * 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
AU4182300A (en) * 1999-03-30 2000-10-16 Merck & Co., Inc. Soluble recombinant endostatin
AU2001236951A1 (en) * 2000-02-18 2001-08-27 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Method for refolding recombinant endostatin
ES2290142T3 (es) * 2000-05-16 2008-02-16 Bolder Biotechnology, Inc. Metodos para replegamiento de proteinas que contiene residuos de cisteina libre.
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
CA2864810A1 (en) 2003-04-18 2004-11-04 Biogen Idec Ma, Inc. Polymer-conjugated glycosylated neublastin
US7524811B2 (en) * 2003-08-29 2009-04-28 Children's Medical Center Corporation Anti-angiogenic peptides from the N-terminus of endostatin
CA2537236A1 (en) * 2003-08-29 2005-05-12 Children's Medical Center Corporation Anti-angiogenic peptides for treating or preventing endometriosis
CA2577755C (en) 2004-08-19 2014-05-13 Biogen Idec Ma Inc. Neublastin variants
CN101123978B (zh) 2004-08-19 2012-12-12 比奥根艾迪克Ma公司 神经胚素变体
MY143274A (en) 2005-12-22 2011-04-15 Genentech Inc Recombinant production of heparin binding proteins
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
CN100398557C (zh) * 2006-04-05 2008-07-02 中国药科大学 血管生成抑制多肽及其制备方法和应用
SG162834A1 (en) 2006-07-14 2010-07-29 Genentech Inc Refolding of recombinant proteins
BRPI0605212B8 (pt) * 2006-12-12 2021-05-25 Univ Rio De Janeiro processo de produção de endostatina dimerizada ou oligomerizada, endostatina dimerizada ou oligomerizada e composição farmacêutica
US8617531B2 (en) * 2006-12-14 2013-12-31 Bolder Biotechnology, Inc. Methods of making proteins and peptides containing a single free cysteine
ES2476253T3 (es) 2007-05-01 2014-07-14 Biogen Idec Ma Inc. P�ptidos de neublastina para su uso en el aumento de la vascularizaci�n en tejido con flujo sanguíneo deteriorado
SG176963A1 (en) 2009-06-22 2012-02-28 Amgen Inc Refolding proteins using a chemically controlled redox state
WO2010151688A2 (en) 2009-06-25 2010-12-29 Amgen Inc. Capture purification processes for proteins expressed in a non-mammalian system
US20130028868A1 (en) * 2011-07-19 2013-01-31 Wenlin Huang Clinical applications of a recombinant human endostatin adenovirus (e10a) injection
CN103992400B (zh) * 2014-05-29 2017-01-04 江苏吴中医药集团有限公司苏州中凯生物制药厂 重组人血管内皮抑素的复性液及其制备、使用方法
PE20170769A1 (es) * 2014-07-14 2017-07-04 Gennova Biopharmaceuticals Ltd Procedimiento novedoso para la purificacion de rhu-gcsf
CN106008702B (zh) * 2016-07-22 2019-11-26 江苏江山聚源生物技术有限公司 一种规模化分离纯化重组人源胶原蛋白的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3537708A1 (de) 1985-10-23 1987-04-23 Boehringer Mannheim Gmbh Verfahren zur aktivierung von t-pa nach expression in prokaryonten
JPH01132598A (ja) 1987-10-14 1989-05-25 Pitman Moore Inc 変性剤溶液中に含まれる組換え蛋白質における分子内ジスルフィド結合の生成を促進する方法
US5789547A (en) 1995-06-07 1998-08-04 Celtrix Pharmaceuticals, Inc. Method of producing insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) with correct folding and disulfide bonding
DE69629826T2 (de) 1995-10-23 2004-07-01 Children's Medical Center Corp., Boston Therapeutische antiangiogenische zusammensetzungen und verfahren
US5854205A (en) * 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
SE9504019D0 (sv) 1995-11-13 1995-11-13 Pharmacia Ab Method for production of proteins

Also Published As

Publication number Publication date
EP1056780A1 (en) 2000-12-06
US6653098B1 (en) 2003-11-25
KR20010034529A (ko) 2001-04-25
JP2002504494A (ja) 2002-02-12
CZ20003058A3 (cs) 2001-09-12
WO1999042486A1 (en) 1999-08-26
PL342495A1 (en) 2001-06-04
AU3294599A (en) 1999-09-06
CN1295580A (zh) 2001-05-16
RU2225728C2 (ru) 2004-03-20
AU766154C (en) 2004-05-20
AU766154B2 (en) 2003-10-09
NO20004170D0 (no) 2000-08-21
BR9908186A (pt) 2000-10-24
IL137995A0 (en) 2001-10-31
NZ506466A (en) 2003-10-31
CA2321958A1 (en) 1999-08-26

Similar Documents

Publication Publication Date Title
NO20004170L (no) FremgangsmÕte ved fremstilling av muse og humant endostatin
AP2000001783A0 (en) Disinfectant and method of making
PL318128A1 (en) Polymer-polyol and method of obtaining polymer-polyols
EP0996632A4 (en) ANGIOSTATIN FRAGMENTS AND METHOD FOR USING THEM
NO975759D0 (no) Inokuleringsmiddel og fremgangsmåte for fremstilling av inokuleringsmiddel
EE03976B1 (et) Erütromütsiinid ja nende valmistamise meetod
PL319213A1 (en) Partially hydrophobous precipitated silic acids, method of obtaining them and their application
PL330811A1 (en) Rapidly cooking rice and methods of obtaining same
NO983641D0 (no) Fremgangsmåte til behandling og farmasöytisk preparat
PL326756A1 (en) Anticarcinogenic vaccine and method of obtaining same
FI980246A0 (fi) Menetelmä keittimen käyttämiseksi ja keitin
PL335903A1 (en) Improved method of obtaining thiazolydinodiones and novel thiazolydinodiones obtained thereby
PL337716A1 (en) Method of obtaining thiazafurin and other c-nucleosides
GB9706070D0 (en) Method of decomposing polychlorodibenzo-p-dioxins and/or polychlorodibenzofurans
EP0777426A4 (en) MOCCASIN MODEL AND ITS FORMING METHOD
PL319451A1 (en) Method of obtaining titanium oxide
DE19749117B4 (de) Pleuelstange und Herstellungsverfahren dafür
PL341205A1 (en) Method of obtaining l-dihydroorotic acid and application thereof
PL325142A1 (en) Novel compounds-derivatives of benzoxazinodione, method of obtaining them and their application
IL122175A (en) Autoclaves and method of operating them
PL317967A1 (en) Novel amidoquinoxalinodione, method of obtaining same and application thereof
PL342185A1 (en) Modified psilium and method of obtaining same
PL319261A1 (en) Steam adsorbent and method of obtaining same
PL341763A1 (en) Triazepinones, method of obtaining them and their therapeutic application
PL327389A1 (en) Novel seco-compounds of thylosine class and method of obtaining them

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application